



mimls
MALAYSIAN INSTITUTE OF
MEDICAL LABORATORY SCIENCES
INSTITUT SAINS MAKMAL PERUBATAN MALAYSIA



19TH ASEAN CONFERENCE OF CLINICAL LABORATORY SCIENCES (ACCLS)

in conjunction with 35th National Scientific Conference of MIMLS



*"The Future-Proof Lab:
Harnessing AI and Sustainable Technology for Global Health"*

29 - 31 July 2026 **The Waterfront Hotel, Kuching, Sarawak**



Tentative Programme:

Trade Exhibition | Pre-Conference Workshop | Student Forum
Plenary Lecture and Symposiums | Oral and Poster Presentation | AACLS Meetings



Call for Abstracts is NOW OPEN!

Abstract / Poster Submission: by 30 June 2026
Early Bird Registration: by 30 June 2026



Register now at
accls2026.mimls.org

Supported By:



REGISTRATION FEES

Type of Registration		Early Bird (Before 30 June 2026)		Regular (Before 28 July 2026)		On-site (29-30 July 2026)	
		USD	RM	USD	RM	USD	RM
AACLS Member	Participant	120	400	130	450	140	500
	Student	100	300	110	350	120	400
Non-AACLS Member	Participant	140	500	150	550	200	600
	Student	120	400	130	450	140	500
Accompanying Person		100	300	110	350	120	400
Day Registration		60	200	70	230	85	250
Pre-Conference Workshop		60	200	70	230		

1. Registration as participant and student includes access to the entire scientific program from 30-31 July 2026 (excluding Pre-Conference Workshop), Trade Exhibition, conference bag and other conference materials.
2. Registration as a student is only applicable for undergraduate students who upload their latest copy of academic transcript during registration.
3. Rates in Ringgit Malaysia (RM) are applicable for Malaysians only.
4. Registration cancelled before 1st July 2026 is eligible for 30% refund of the registration fees paid. Registration cancelled after 2nd July 2026 is not eligible for any refund.

CALL FOR PAPERS

The ACCLS 2026 Scientific Committee invites submission for oral / poster presentations on all aspects of Medical Laboratory Sciences that have not previously been published or presented.

Guidelines for Abstract Preparation

Language	Abstract must be written and presented in English.
Title	Title of abstract should not exceed 30 words. Do not use abbreviations in the title.
Name	The authors are to write their name as Given name, Surname/Family name (e.g. Yun Fatt, Chow; Aminah Ahmad; Bhavani Muthusamy; Francis Light). Do not include titles and degrees. Please bold the name of the presenter.
Institution	List the author's institution by department, institution, city and country.
Abstract words	Abstract is to have 200-300 words.
Abstract body	Abstract is to have an introduction/aim, method, results, and conclusion.
Abbreviations	Define the abbreviation in the first use.
Data units	Data units must be in the International System of Units (SI units).
Keywords	Keywords must not be less than 3 words and not more than 5 words. Arrange the keywords in alphabetical order.
Font	Abstract to use font Times New Roman with a font size of 12 points.
Reproduce	Abstract reproduced will be as is submitted with no editing. The author is responsible for all spelling, grammatical or scientific errors.
Conflict of interest	The author must disclose conflict of interest to avoid any commercial bias.
Copyright	By submitting the abstract, the author grants the ACCLS 2026 the exclusive right to first publish the abstract and thereafter a non-exclusive right to publish, display and store the abstract in all forms, formats, and media. No fees shall be paid to the author by ACCLS 2026 for the license granted herein. The author will retain the copyright of his or her abstract as well.
Withdrawal	Authors who wish to withdraw their abstract must send a written request to the Scientific Committee at mimlsabs09@yahoo.com

ABSTRACT SUBMISSION

Use the following excerpt as a format guide:

INVESTIGATION OF THE CHROMOSOME 6 INSTABILITY AND THE MAPK SIGNALING PATHWAYS IN HUMAN OSTEOSARCOMA

¹ M. Rozi Ramli, ² **M.M. Hamdi**, ³ Mohd Aminudin Mustapha
⁴ Mohamad Zulkarnaen Ahmad Narihan

¹Department of Pathology, Sarawak General Hospital (SGH), Jalan Hospital (SGH), Jalan Hospital, 93586 Kuching, Sarawak.

²Department of Para-Clinical Science, Faculty of Medicine and Health Sciences (FMHS), UNIMAS, 94300 Kota Samarahan, Sarawak.

³Pre-University Centre, UNIMAS, 94300 Kota Samarahan, Sarawak.

⁴Department of Pathology, FMHS, UNIMAS, 94300 Kota Samarahan, Sarawak.

*Presenter's email: mmhamdi@fmhs.unimas.my

Abstract

Osteosarcoma is the most common primary malignancy of bone with worldwide incidence of 2 to 3 million/year. This tumour usually develops at distal part of fast growing bone and associated with instability of chromosome 6. Despite that, the preceding molecular mechanism leading to the instability is not fully known. Following the local ethical committee review, from a total of 30 cases within 7 years period (from October 2008 to October 2015). The study aimed to investigate the copy number of gene encoding vascular endothelial growth factor (VEGF) located at chromosome 6p21 using Fluorescence In Situ Hybridization (FISH) and the general chromosomal instability as indicated by micronuclei formation. In addition, VEGF, Hypoxia inducible factor (HIF) and p53 diagnostic immunohistochemistry (IHC) staining were performed as to investigate relationship of hypoxic stress and tumour growth suppress. Furthermore, the mitogen activated protein kinase (MAPK) cellular proliferation pathway molecules; ERK, p38 and JNK IHC were also examined. Our findings showed VEGF expression at both protein and gene level (6p21) indicating likelihood of neovascularization. On top of that, expressed ERK, p38 but not JNK; and expressed HIF & p53 in those cases suggest tumour cell survival by evading the natural cell death program, apoptosis. In conclusion, this study presented a possible molecular mechanism underlying chromosomal instability in human osteosarcoma.

Keywords: Osteosarcoma; mitogen activated protein kinase; chromosomal instability; 6p21

ABSTRACT REVIEW AND SELECTION

Authors are encouraged to submit full paper and if selected by the Editorial Board, will be published as proceedings in the Malaysian Journal of Medical Laboratory Sciences (MJMLS).

The ACCLS 2026 Scientific Committee reserves the right to select papers relevant to the session. Presenters may present papers without having their papers published in congress proceedings or MJMLS.

Abstract Submission Deadline : 30 June 2026
Presenter's Registration Deadline : 10 July 2026



Submit your abstract at
accls2026.mimls.org

CONFERENCE VENUE



THE WATERFRONT HOTEL

68, Jalan Tun Abang Haji Openg,
93000 Kuching, Sarawak, Malaysia.

Tel : +60 82 227 227

Fax : +60 82 227 277

Email : info@thewaterfrontkuching.com

Website : www.thewaterfrontkuching.com

LOCATION

Perched on top of Plaza Merdeka Shopping Center, The Waterfront Hotel is located in the heart of Kuching City, where decades-old buildings sit side by side with modern buildings. With one of the best view of the Padang Merdeka and the Sarawak River, the hotel is not only a place to rest, but a start of your adventures in Kuching City.

Tourists attractions within walking distance:

- Carpenter Street
- India Street
- Kuching Waterfront
- Darul Hana Bridge
- Tua Pek Kong Temple
- Chinese History Museum
- Borneo Cultures Museum
- St. Thomas's Cathedral



ACCOMMODATION

The ACCLS 2026 Organising Committee recommends our delegates to stay at **The Waterfront Hotel** and enjoy special rates from the hotel.

Delegates are kindly requested to make their room reservations directly with the hotel by completing the hotel reservation form and submitting it via email to reservation@thewaterfrontkuching.com. We encourage you to secure your accommodation well in advance to ensure availability.



Alternatively, you can also look for more places to stay around Kuching city through various booking platforms. Accommodation of various ranges from budget to luxury hotels are widely available.



PEJADAT PENDAFTAR SYARIKAT
(Registry of Companies)
MALAYSIA

BORANG 8
AKTA SYARIKAT 1965
[Seksyen 16 (4)]

No. Syarikat


254676	P
--------	---

PERAKUAN PEMERBADANAN SYARIKAT AWAM

Ini adalah untuk memperakui bahawa
MALAYSIAN INSTITUTE OF MEDICAL LABORATORY SCIENCES
telah diperbadankan di bawah Akta Syarikat 1965, pada dan
mulai dari 31 haribulan Disember, 1992, dan bahawa
syarikat ini adalah sebuah syarikat berhad menurut jaminan.

Diberi di bawah tandatangan dan meterai saya di Kuala Lumpur
pada 31 haribulan Disember, 1992.




(RAJA HABIBAH BTE RAJA SAIDIN)
Penolong Pendaftar Syarikat
Malaysia



MENTERI PERDAGANGAN DALAM NEGERI
DAN HAL EHWAL PENGGUNA MALAYSIA

AKTA SYARIKAT 1965

LESEN DI BAWAH SEKSYEN 24(1)

MALAYSIAN INSTITUTE OF MEDICAL LABORATORY SCIENCES

Bahawasanya telah dibuktikan dengan puashati saya:

- a) bahawa suatu syarikat bernama MALAYSIAN INSTITUTE OF MEDICAL LABORATORY SCIENCES (kemudian daripada ini disebut sebagai "INSTITUTE" tersebut) hendak ditubuhkan sebagai suatu syarikat berhad bagi menganjurkan tujuan-tujuan khairat atau berguna yang dinyatakan dalam Tatawujud Persatuan "INSTITUTE" tersebut;
- (b) bahawa "INSTITUTE" tersebut bercadang hendak menggunakan semua keuntungannya dan lain-lain pendapatan untuk menganjurkan tujuan-tujuan khairat dan berguna yang tersebut itu;
- (c) bahawa "INSTITUTE" tersebut adalah dilarang oleh Perlembagaannya dari membayar apa-apa dividen kepada ahli-ahlinya.

Maka dalam ini saya, Dato' Haji Abu Hassan bin Haji Omar, Menteri Perdagangan Dalam Negeri dan Hal Ehwal Pengguna Malaysia, dengan ini mengarahkan, menurut kuasa-kuasa yang diberi kepada saya oleh Seksyen 24(1), Akta Syarikat 1965, bahawa "INSTITUTE" tersebut didaftarkan sebagai suatu syarikat dengan tanggungan berhad tanpa perkataan "BERHAD" kepada namanya.

Bertarikh:

18 Ws. Sept., 1992.

(DATO' HAJI ABU HASSAN BIN HAJI OMAR)

Menteri Perdagangan Dalam Negeri
dan Hal Ehwal Pengguna Malaysia.



MENTERI PERDAGANGAN DALAM NEGERI
DAN HAL EHWAL PENGGUNA MALAYSIA


AKTA SYARIKAT 1965

PERSETUJUAN DI BAWAH SEKSYEN 22(1)

MALAYSIAN INSTITUTE OF MEDICAL LABORATORY SCIENCES

Menurut Seksyen 22(1), Akta Syarikat 1965, saya Dato' Haji Abu Hassan bin Haji Omar, Menteri Perdagangan Dalam Negeri dan Hal Ehwai Pengguna Malaysia, dengan ini memberi persetujuan saya untuk sebuah syarikat yang akan dipemerbadankan iaitu MALAYSIAN INSTITUTE OF MEDICAL LABORATORY SCIENCES menggunakan perkataan "INSTITUTE" dan menggugurkan perkataan "BERHAD" di dalam namanya.

Bertarikh: 18 Sept. 1992.



(DATO' HAJI ABU HASSAN BIN HAJI OMAR)
Menteri Perdagangan Dalam Negeri
dan hal Ehwai Pengguna Malaysia



Malayan Banking Berhad (3813-K)
14th Floor, Menara Maybank, 100 Jalan Tun Perak, 50050 Kuala Lumpur, Malaysia

PETALING JAYA MAIN

MALAYSIAN INSTITUTE OF MEDICAL LABORATOR
1-5-14 JALAN 1/50
DIAMOND SQUARE OFF
JALAN GOMBAK 53000
KUALA LUMPUR WP

MUKA/ 頁 /PAGE : 4
TARIKH PENYATA :
結單日期 : 30/04/26
STATEMENT DATE
NOMBOR AKAUN :
戶號 : 014169424162
ACCOUNT NUMBER

PROTECTED BY PIDM UP TO RM250,000 FOR EACH DEPOSITORCORPORATE CURRENT ACCOUNT

URUSNIAGA AKAUN/ 戶口進支項 /ACCOUNT TRANSACTIONS

TARIKH MASUK 進支日期 ENTRY DATE	TARIKH NILAI 灰過賬日期 VALUE DATE	BUTIR URUSNIAGA 進支項說明 TRANSACTION DESCRIPTION	JUMLAH URUSNIAGA 銀碼 TRANSACTION AMOUNT	BAKI PENYATA 結單存餘 STATEMENT BALANCE
		THE REVISED STAMP DUTY CHARGES ON CHEQUE RELATED INSTRUMENTS WHICH WAS OUTLINED IN THE FINANCE ACT 2024 (GAZETTED ON 31ST DECEMBER 2024). . KINDLY BE INFORMED THAT EFFECTIVE 1ST JANUARY 2025, THE STAMP DUTY CHARGES FOR CHEQUE RELATED INSTRUMENTS FOR CHEQUE BOOK, BANKER'S CHEQUE / DEMAND DRAFT, TRAVELLER'S CHEQUE, FOREIGN CHEQUE, MIDF / MIH PUBLIC ISSUE HAS BEEN REVISED FROM RM 0.15 TO RM 1.00 PER CHEQUE LEAF. . FOR ANY FURTHER CLARIFICATIONS / ENQUIRIES YOU MAY LIASE WITH THE NEAREST BRANCH OR CONTACT US AT 1-300-88-6688 . PLEASE REFER TO THE ANNOUCEMENTS SECTION ON THE MAYBANK2U WEBSITE FOR LATEST UPDATES. . THANK YOU FOR YOUR UNDERSTANDING & KIND SUPPORT. .		

BAKI LEGAR ▪ BAKI AKHIR - CEK BELUM JELAS
可應用存餘 ▪ 截止結餘減未過賬灰
LEDGER ▪ ENDING BALANCE - UNCLEARED CHEQUES
BALANCE

Perhatian / Note
(1) Semua maklumat dan baki yang dinyatakan di sini akan dianggap betul melainkan Bank telah dimaklumkan secara bertulis tentang sebarang ketidaktepatan dalam tempoh 21 hari.
若银行在21天内未获得书面通知于任何差异，所有显示的账项及余额将被视为正确。
All items and balances shown will be considered correct unless the Bank is notified in writing of any discrepancies within 21 days.
(2) Sila beritahu kami sebarang pertukaran alamat secara bertulis.
請通知本行在何地址更換。
Please notify us of any change of address in writing.

Wang yang keluar berlebihan
ditandakan dengan DR

本欄內誌DR者為結欠

Overdrawn balances are
denoted by DR